Index
Note: Page numbers followed by “f”, “t”, and “b” refers to figures, tables and boxes, respectively.
A
Acute myeloid leukemia (AML),
187
Acyl carrier protein (ACP),
35–37
Adenosine triphosphate (ATP),
364
Affinity-based cell targeting,
257–258
surface functional groups,
260
enzymatic modification,
261
Aldehyde-based reactions,
46
Allogeneic islet transplantation,
255
Antibody–drug conjugates (ADCs),
159
Anticancer therapeutics,
72–73
Anti-infective probiotic therapy,
80
Aptamer cell surface sensors,
362–364
Aptamer-mediated immobilization,
330–331
Artificial veto cell engineering,
10–11
Atom transfer radical polymerization (ATRP),
335–336
Auto-signaling loops, creating,
15–16
Azide- and alkyne-based bioorthogonal reactions,
47–51
classical and modified Staudinger ligation reactions,
48–49
copper-catalyzed [3+2] azide–alkyne cycloaddition,
49–50
strain-promoted azide–alkyne cycloaddition reactions,
50–51
B
Baby hamster kidney (BHK) cells,
228–229
Bacillus subtilis spores,
71t
Bacterial surface display,
64–65
Bacterial surface proteins and sugars, chemical re-engineering of,
81b
Barstar-mediated immobilization,
330
Benzotriazole carbonate (BTC),
283–284
β-barrel model,
Bioorthogonal chemical ligation reactions,
44–45
for glycan labeling,
45–54
aldehyde-based reactions,
46
azide- and alkyne-based bioorthogonal reactions,
47–51
classical and modified Staudinger ligation reactions,
48–49
copper-catalyzed [3+2] azide–alkyne cycloaddition,
49–50
ketone-based reactions,
47
photoactivated ligation reactions,
52–54
strain-promoted azide–alkyne cycloaddition reactions,
50–51
thiol-based chemistry,
51–52
in MOE-based applications,
54–57
imaging of living cells,
54–56
in vivo labeling/imaging,
56
MOE extends beyond N-acyl-modified sialic acid,
54
tissue engineering, stem cell research, and regenerative medicine,
56–57
applications of cell surface engineering using,
149–151
cell–particle hybrid synthesis,
151
spatial control of cell growth on solid surfaces and tissue engineering,
149–150
surface conjugation of macromolecules,
150–151
methods for engineering cell surfaces with,
146–149
covalent binding of biotin to cell surfaces,
147–148
noncovalent binding of biotin to cell surface,
148–149
Biotin–streptavidin
-mediated two-step protein transfer,
133–135
Biotinylated antibodies,
149
Bone marrow endothelial cells (BMECs),
190–191
Bone morphogenetic protein-2 (BMP-2),
322–323
Bordetella pertussis,
71t
C
C8-binding protein (C8bp),
128
Caenorhabditis elegans,
44
CAM (cellular adhesion molecules),
177f
metabolic oligosaccharide engineering (MOE) for,
57
Carbon nanotubes (CNTs),
263
5-(6)-Carboxyfluorescein diacetate (CFDA),
352–353
Caveolae,
CD30
+ lymphoma cells, targeting,
259
CD317/tetherin,
Cell identity, computation of,
159–161
accurate identification of cell type,
160–161
logic-based cancer targeting and therapy,
161
chemical modification of,
28
categories of cell capsules,
218
challenges and future perspectives,
231–232
cells-core/shell microcapsules,
219–220
liquid-core/shell microcapsules,
219
matrix-core/shell microcapsules,
218–219
purpose and requirements of,
218
therapeutic applications of,
226–231
in central nervous system (CNS) diseases,
230–231
liver disease treatment,
231
Cell surface biotinylation,
149
noncovalent
for bioimaging applications,
114–115
to manipulate cell biological fate,
115–116
Cell surface protein interactome (CSPI),
18
enzymatic modification,
261
embryonic stem cells (ESCs),
256
hematopoietic stem cell transplantation (HSCT),
254–255
induced pluripotent stem cells (IPSCs),
256–257
mesenchymal stem cells (MSCs) therapy,
256
pancreatic islet transplantation,
255–256
candidate therapeutic agents and cell types for,
264–266
nanosystem types and key characteristics,
262–264
“Trojan horse” cell therapy for cancers (case study),
266–268
in vitro study using engineered microdevices,
351–360
control over cell spatial and temporal arrangements,
352–355
mimicking the
in vivo microenvironment,
358–360
probing and manipulation of,
360–364
cell surface Aptamer sensors for,
362–364
chemical modification of cell surfaces with adhesion molecules,
364
genetically encoded proteins for,
360–361
Cell–particle hybrid synthesis,
151
Cells-core/shell microcapsules,
219–220
Cellular DNA patches, targeting,
161–164
Cellular migration, multistep paradigm of,
176–181
Cellular networks, rewiring,
8–9
Charge-neutralized transmembrane DNA pores,
167–168
Chemical exchange saturation transfer (CEST),
247–248
“Chemical reporter,”,
35–37
Chemical vapor deposition (CVD),
282–283
Chinese hamster ovary (CHO) cells,
228–229
Cholesterol-tethering of biomolecules,
123–124
advantages/disadvantages of,
125–126
to create synthetic receptors,
124–125
to membrane surfaces,
124
Cholesterol-to-phospholipid (C/P) molar ratio,
123–124
Choroid plexus (CP) cells,
230
Circulating thymic progenitor, CTP,
180
Cis loop-back protein (CLBP),
13f,
15,
16
Classical and modified Staudinger ligation reactions,
48–49
Clostridium perfringens,
72
“Clusters of differentiation” (CDs),
159
Collagen-binding domain-mediated immobilization,
326–327
Complement regulatory proteins,
178
Contact hypersensitivity model (CHS),
184
Copper-catalyzed [3+2] azide–alkyne cycloaddition,
49–50
Correlative microscopy,
169
Covalent cell surface reaction, methods and technology of,
29–37
direct chemical modification,
29–35
future perspectives,
38–39
indirect chemical modification,
35–37
Covalent modification of cells,
37–38
Cryo-electron tomography (cryoET),
168
“Cu-free click chemistry,”,
35–37
“Custom-designed killer cells,”,
127
CXCL12 abundant reticular (CAR) cells,
190–191
Cytotoxic T-cells (CTLs),
126
D
Danielli–Davison model,
2–3
Dendritic cells (DCs),
358
Diabetes treatment, encapsulated cells in,
226–228
Diffusion modulated macromolecular cell derivatization (DMMCD),
284–285,
285f
Dimethyl-prostaglandin E2 (dm-PGE2),
187
1,2-Distearoyl-sn-glycero-3-phosphatidylethanolamine (DSPE),
287
channels and pores spanning lipid membrane,
166–168
charge-neutralized transmembrane pores,
167–168
cross-linked receptors trigger robust signaling responses,
164
nanostructures construction,
158f
activation of signaling pathways in target cells,
164–166
transmembrane channel,
166
E
Elastin-like peptides,
224
Elastin-like polypeptides,
318
Electrostatic interactions mediated cell surface modification,
113–116
for bioimaging applications,
114–115
cell biological fate, manipulating,
115–116
harnessing electrostatic interactions,
113–114
Embryonic stem cells (ESCs),
256
Encapsulated cells, therapeutic applications of,
226–231
central nervous system (CNS),
230–231
challenges and future perspectives,
231–232
Engineered polymer thin films,
303–305
enhancing cell and drug delivery,
303–305
in vivo modification of cells and tissues,
308–309
molecular camouflage and nano-encapsulation,
297–303
covalent conjugation of polymer monolayer films to cell surfaces,
283–286
electrostatic adsorption of polymers,
288–290
general design principles and considerations,
282–283
membrane-anchored polymer thin films,
286–288
multilayer polymer thin films,
290–296
Enhanced molecular transport,
284–285
Enzymatic engineering-based approaches, to improve cellular therapies
cell surface carbohydrates modification on proteins and lipids,
185–191
cell surface glycoconjugates, modification of,
186–187
cytokine and growth factor induced expression of GTs within cells,
187–188
recombinant GTs
ex vivo use,
188–191
cellular migration
role of glycosyltransferases in controlling,
182–185
changes on cell surface structures that deter migration and metastasis,
191–200
metabolic inhibition of glycosyltransferases,
195–200
selectin–selectin ligand axis in metastasis,
191–195
E-selectin ligands in therapy and disease,
181–182
modification of cell surface,
200
Enzymatic transformations,
28
Epidermal growth factor (EGF)-like domain,
178
Epithelial-to-mesenchymal transition (EMT),
182
fucosyltransferases (FTs) and,
184
glycosyltransferases (GTs) involvement in creation of,
183–184
aptamer-mediated immobilization,
330–331
ECM-derived proteins and growth factors, covalent immobilization of,
319–322
immobilization of growth factors,
322–326
protein/peptide tags for immobilization,
326–330
F
Factor XIIIA transglutaminase catalyzed immobilization,
327–329
Fas ligand bound to SA (SA-FasL),
134
Fluid mosaic model for cell membranes,
2–3, ,
122
Fluorescence light microscopy,
168–169
Fluorescence resonance energy transfer (FRET),
131
Fluorescence-activated cell sorting (FACS),
76–77,
109f
Fluorescent nanodiamonds (FNDs),
244
5-Fluorocytosine (5-FC),
267
Fucosyltransferases (FTs),
184
and E-selectin ligand formation,
184
G
G protein-coupled receptors (GPCRs),
G-CSF (granulocyte-colony stimulating factor),
187
Genetically encoded calcium indicators (GECIs),
367
Genetically modified organisms (GMOs),
64
risks associated with,
65b
Glial-cell-derived neurotrophic factor (GDNF),
230
Glioblastoma stem cells (GSCs),
266–267
Glycans
expressed at on bacterial surfaces,
78b
Glycophorin,
Glycoprotein production,
80–82
Glycosyltransferases (GTs),
176
in creation of E-selectin ligands,
183–184
perturbation in expression of,
195
primers and metabolic decoys,
199–200
role in controlling cell migration,
182–185
substrate-analogous inhibitors,
197–199
Gorter–Grendel lipid bilayer model,
2–3
GPI-anchored proteins (GPI-AP), ,
127–133
advantages and limitations of,
130–131
“GPS”(glycosyltransferase-programmed stereosubstitution),
189
Gramicidin A,
Gram-negative organisms,
64,
67
Gram-positive bacteria,
64
Gram-positive organisms,
67–68
Granulocyte macrophage colony stimulating factor (GM-CSF),
150–151
Growth factors
and ECM components, interactions between,
323t
H
Harnessing electrostatic interactions,
113–114
Hematopoietic stem cell transplantation (HSCT),
254–255
Heterobifunctional PEG,
304
Heterologous expression systems,
64,
65f
re-engineering bacterial surfaces with,
66–70
Heterologous surface proteins
anticancer therapeutics,
72–73
bacteria expressing,
70–77
re-engineering bacterial surfaces with,
66–70
gram-negative organisms,
67
gram-positive organisms,
67–68
outer membrane vesicles and bacterial ghosts,
69–70
surface proteins and solutes, interactions between,
74–77
vaccines against cancer,
73–74
vaccines against infectious disease,
70–72
Heterologous surface sugars
bacteria expressing,
79–82
anti-infective probiotic therapy,
80
glycoprotein production,
80–82
vaccines against infectious disease,
79–80
re-engineering bacterial surfaces with,
77–79
High endothelial venules (HEVs),
178–180
Homologous restriction factor (HRF),
128
Human mesenchymal stem cells (hMSCs),
224,
245
Human umbilical vein endothelial cells (HUVECs),
354–355
Hydrazide-activated biotin,
33–35
biofucntionalization of,
315
dispersion/precipitation polymerization,
336–337
water-in-oil heterogeneous emulsion,
335–336
I
Ice nucleation protein (INP),
67,
67
Imaging modalities for NP engineered cells,
242–244,
244
Immunological synapse (IS),
358
Inner membrane (IM),
64,
67
Insulin-like growth factor-II (IGF-II),
325
Intracellular internalization of NPs,
244–245
Iron oxide NPs (IONPs),
163,
245
J
K
Ketone-based reactions,
47
Ketone-functionalized cells,
37
L
Lactic acid bacteria,
71t
dendritic cells (DCs),
266
Lipid-mediated cell surface engineering,
122–123
using cholesterol-modified proteins,
123–126
using proteins with hydrophobic domains,
133
with GPI-anchored proteins,
127–133
with palmitoylated proteins,
126–127
biotin–streptavidin-mediated,
133–137
lipid-metal chelator-mediated,
136–137
palmitoylated protein A-mediated,
135–136
Lipidomics,
Liquid-core/shell microcapsules,
219
Listeria monocytogenes,
71t,
72,
73
Live bacteria in cancer therapy,
72,
73
Living cells
bioconjugation reactions in,
43
bioorthogonal chemical ligation reactions for glycan labeling,
45–54
aldehyde-based reactions,
46
azide- and alkyne-based bioorthogonal reactions,
47–51
bioorthogonal ligation reactions, exploitation in MOE-based applications,
54–57
ketone-based reactions,
47
photoactivated ligation reactions,
52–54
thiol-based chemistry,
51–52
development, advances, and applications of glycan-specific technologies,
43
Logic-based cancer targeting and therapy,
161
Lymphocyte function-associated antigen 3 (LFA-3),
128–129
M
Major histocompatibility complex (MHC),
Maleimide-based covalent modification,
32–33
Matrix-core/shell microcapsules,
218–219
Mesenchymal stem cells (MSCs),
30–31,
38,
101–102,
103f,
109–110,
224,
246–247,
258–259,
259–260,
261–262,
265,
297–298
Metabolic approach of cell surface engineering,
102f
Metabolic oligosaccharide engineering (MOE),
44
extends beyond N-acyl-modified sialic acid,
54
Methoxy poly (ethylene glycol) (mPEG),
299
Monocytes as drug carriers,
266
Mouse embryonic fibroblast cells (MEFs),
357–358
Mouse embryonic stem cells (mESCs),
357–358
Mucosal vaccinology, surface-engineered bacteria in,
70,
71t
Multilayer polymer thin films,
290–296
N
N-(3β)-cholesterylglycine,
124
cell membrane functionalization,
245–246
intracellular internalization of NPs,
244–245
Neural stem/progenitor cells (NSPCs),
329–330
Nitrilotriacetic acid ditetradecylamine (NTA-DTDA),
136
3 (Nitrilotriacetic acid) ditetradecylamine (NTA
3-DTDA),
136
Noncanonical amino acids (ncAAs),
81–82
Noncovalent functionalization, of cell surface,
100–101
anchoring biomolecules on cell surface,
109–113
cell interactions, enhancing,
105
electrostatic interactions mediated cell surface modification,
113–116
bioimaging applications, noncovalent cell surface modification for,
114–115
cell biological fate, manipulating,
115–116
harnessing electrostatic interactions,
113–114
noncovalent immobilization of agents,
102–105
programmed cell–substrate and cell–cell assembly,
105–109
targeting ability of surface engineered cells,
101–102
Nongenetic cell surface modifications,
100
Nucleic acids, construction and computation with,
157
cell identity, computation of,
159–161
accurate identification of cell type,
160–161
logic-based cancer targeting and therapy,
161
cellular DNA patches targeted to cancer cells,
161–164
DNA channels and pores spanning lipid membrane,
166–168
charge-neutralized transmembrane DNA pores,
167–168
transmembrane DNA channel,
166
robust signaling responses, triggering,
164
signaling pathways in target cells, activating,
164–166
O
“Off-target” toxicities,
159
using cholesterol-modified proteins,
123–126
using proteins with hydrophobic domains,
133
with GPI-anchored proteins,
127–133
with palmitoylated proteins,
126–127
O-sialoglycoprotein endopeptidase (OSGE),
200
Outer membrane vesicles (OMVs),
69–70,
71t
Oxyamine-based liposomes,
106f
P
A-mediated two-step protein transfer,
135–136
Pancreatic islet cells (PICs),
226
Paroxysmal nocturnal hemoglobinuria (PNH),
128
Pathogen-associated molecular patterns (PAMPs),
70
Peripheral membrane proteins,
2–3
Peripheral node addressins (PNAds),
178–180
Phosphatidylinositol phospholipase C (PI-PLC),
128,
130
Photoactivated ligation reactions,
52–54
Photoaffinity labeling (PAL),
52
Physical targeting strategies,
261–262
Platelet-activating factor (PAF),
Poly(2-dimethylamino ethylmethacrylate) (PDMAEMA),
300
Poly(amidoamine) (PAMAM) dendrimers,
293–294
Poly(caprolactone) (PCL),
225
Poly(L-lysine)-graft-poly (ethylene glycol) (PLL-g-PEG),
115,
288–289
Poly(N-vinylpyrrolidone) (PVPON),
295
Polydiacetylene (PDA),
114
Polyelectrolyte multilayer (PEM) films,
292
Polyethylene oxide (PEO) polymer,
149
electrostatic adsorption of,
288–290
Probiotic therapy, anti-infective,
80
Prostate-specific antigen (PSA),
57
of antigen-presenting cells with GPI-anchored MHC complexes,
131–132
biotin–streptavidin-mediated two-step,
133–135
advantages and limitations,
130–131
lipid-metal chelator-mediated two-step,
136–137
palmitoylated protein A-mediated two-step,
135–136
using proteins with hydrophobic domains,
133
Protein–protein interaction,
18
Proximity-based imaging probes,
242
Pseudomonas aeruginosa capsular polysaccharide,
77–79
R
Rational for cell surface engineering,
144
Recombinant DNA technology,
321,
326
Recombinant genetic solutions
risks associated with,
65b
Reversible addition-fragmentation chain transfer (RAFT),
335–336,
336–337
S
Salmonella enterica serovar Typhimurium,
67,
73
Salmonella vaccine strain,
73–74
carbohydrate ligands of,
179f
mediate tumor progression and metastasis,
192f
Shigella lipopolysaccharide,
77–79
therapeutic flexibility,
16–17
Singer–Nicolson fluid mosaic model,
2–3,
Single-walled carbon nanotubes (SWNTs),
244–245
Smooth muscle cells (SMCs),
333–334
Sonic hedgehog (SHH),
330
Spatial control of cell growth on solid surfaces,
149–150
Src homology 3 (SH3) domain-mediated immobilization,
329
SR-mediated cellular cytotoxicity (SRMCC),
127
Stage-specific embryonic antigen 1 (SSEA-1),
245–246
Staudinger ligation reactions,
48–49
mesenchymal stem cells (MSCs),
265
neural stem cells (NSCs),
265
Strain-promoted azide–alkyne cycloaddition (SPAAC),
50,
50–51
Streptococcus bacteria,
166
Streptomyces avidinii,
145
Super-resolution fluorescence microscopy imaging,
168–169
Super-resolution microscopy techniques,
4–5
Surface energy transfer (SET) “nanoruler” principle,
246
Surface functional groups,
100,
260
Surface proteins and solutes, interactions between,
74–77
Surrogate receptor (SR),
125,
127
Synthetic nanoparticles,
335
poly(ethylene glycol),
225
T
Targeted transport of payload to cell surface,
161–166
activation of signaling pathways,
164–166
DNA cross-linked receptors,
164
Targeting ability of surface engineered cells,
101–102
Tetraspanin webs (TEMs),
Therapeutic agents, cell-based delivery of,
264
Thiol-based cell surface modification,
33–35
Thiol-based labeling,
51–52
Toxic shock syndrome toxin-1 (TSST1),
133,
133
Trans signal conversion,
11–14
Trans signal converter proteins (TSCP),
12,
15
Trans signal redirecting protein (TSRP),
13f,
14,
15,
16
Transglutaminase factor XIIIA (FXIIIa),
327–328
Tris-(carboxyethyl)-phosphine (TCEP),
51–52
Tumor immunotherapy
protein transfer of GPI-APs in,
132–133
Tumor membrane vesicles (TMVs),
130,
132,
132
Tumor necrosis factor-alpha (TNF-α),
180,
229,
267
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),
14–15,
72–73,
267
Tumor-associated macrophages (TAMs),
266,
267
biotin–streptavidin-mediated,
133–137
lipid-metal chelator-mediated,
136–137
palmitoylated protein A-mediated,
135–136
pancreatic islet transplantation for,
255
U
V
against infectious disease,
70–72
Vascular cell adhesion molecule-1 (VCAM-1),
181
Vascular endothelial adhesion molecule (VCAM),
305
W
Water-in-oil heterogeneous emulsion,
335–336
Y
Yersinia pseudotuberculosis,
72